TY - JOUR
T1 - Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor-κB/mitogen-activated protein kinase
AU - Chuma, Makoto
AU - Sakamoto, Naoya
AU - Nakai, Akira
AU - Hige, Shuhei
AU - Nakanishi, Mitsuru
AU - Natsuizaka, Mitsuteru
AU - Suda, Goki
AU - Sho, Takuya
AU - Hatanaka, Kanako
AU - Matsuno, Yoshihiro
AU - Yokoo, Hideki
AU - Kamiyama, Toshiya
AU - Taketomi, Akinobu
AU - Fujii, Gen
AU - Tashiro, Kosuke
AU - Hikiba, Yoko
AU - Fujimoto, Mitsuaki
AU - Asaka, Masahiro
AU - Maeda, Shin
N1 - Funding Information:
Ministry of Education, Culture, Sports, Science and Technology, Japan (to N.S.); Japan Society for the Promotion of Science (24390185, 24659359); Ministry of Health, Labour and Welfare Japan; Japan Health Sciences Foundation; grants-in-aid for scientific research (22300317) and Uehara Memorial Foundation (to S.M.).
PY - 2014/2
Y1 - 2014/2
N2 - Heat shock factor 1 (HSF1), a major transactivator of stress responses, has been implicated in carcinogenesis in various organs. However, little is known about the biological functions of HSF1 in the development of hepatocellular carcinoma (HCC). To clarify the functional role of HSF1 in HCC, we established HSF1-knockdown (HSF1 KD) KYN2 HCC cells by stably expressing either small hairpin RNA (shRNA) against HSF1 (i.e. HSF1 KD) or control shRNA (HSF1 control). Tumorigenicity was significantly reduced in orthotopic mice with HSF1 KD cells compared with those with HSF1 control cells. Reduced tumorigenesis in HSF1 KD cells appeared attributable to increased apoptosis and decreased proliferation. Tumor necrosis factor-α-induced apoptosis was increased in HSF1 KD cells and HSF1-/- mouse hepatocytes compared with controls. Decreased expression of IκB kinase γ, a positive regulator of nuclear factor-κB, was also observed in HSF1 KD cells and HSF1-/- mouse hepatocytes. Furthermore, expression of bcl-2-associated athanogene domain 3 (BAG3) was dramatically reduced in HSF1 KD cells and HSF1-/- mouse hepatocytes. We also found that epidermal growth factor-stimulated mitogenactivated protein kinase signaling was impaired in HSF1 KD cells. Clinicopathological analysis demonstrated frequent overexpression of HSF1 in human HCCs. Significant correlations between HSF1 and BAG3 protein levels and prognosis were also observed. In summary, these results identify a mechanistic link between HSF1 and liver tumorigenesis and may provide as a potential molecular target for the development of anti-HCC therapies.
AB - Heat shock factor 1 (HSF1), a major transactivator of stress responses, has been implicated in carcinogenesis in various organs. However, little is known about the biological functions of HSF1 in the development of hepatocellular carcinoma (HCC). To clarify the functional role of HSF1 in HCC, we established HSF1-knockdown (HSF1 KD) KYN2 HCC cells by stably expressing either small hairpin RNA (shRNA) against HSF1 (i.e. HSF1 KD) or control shRNA (HSF1 control). Tumorigenicity was significantly reduced in orthotopic mice with HSF1 KD cells compared with those with HSF1 control cells. Reduced tumorigenesis in HSF1 KD cells appeared attributable to increased apoptosis and decreased proliferation. Tumor necrosis factor-α-induced apoptosis was increased in HSF1 KD cells and HSF1-/- mouse hepatocytes compared with controls. Decreased expression of IκB kinase γ, a positive regulator of nuclear factor-κB, was also observed in HSF1 KD cells and HSF1-/- mouse hepatocytes. Furthermore, expression of bcl-2-associated athanogene domain 3 (BAG3) was dramatically reduced in HSF1 KD cells and HSF1-/- mouse hepatocytes. We also found that epidermal growth factor-stimulated mitogenactivated protein kinase signaling was impaired in HSF1 KD cells. Clinicopathological analysis demonstrated frequent overexpression of HSF1 in human HCCs. Significant correlations between HSF1 and BAG3 protein levels and prognosis were also observed. In summary, these results identify a mechanistic link between HSF1 and liver tumorigenesis and may provide as a potential molecular target for the development of anti-HCC therapies.
UR - http://www.scopus.com/inward/record.url?scp=84893349967&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893349967&partnerID=8YFLogxK
U2 - 10.1093/carcin/bgt343
DO - 10.1093/carcin/bgt343
M3 - Article
C2 - 24130164
AN - SCOPUS:84893349967
SN - 0143-3334
VL - 35
SP - 272
EP - 281
JO - Carcinogenesis
JF - Carcinogenesis
IS - 2
M1 - bgt343
ER -